TXNIP and colorectal cancer: To assess the relative expression change of TXNIP after chemotherapy, compared to other transcripts, we used primary colorectal cancer cell lines (DLD1 and HCT15) and treated them with a clinically relevant concentration (10 μM) (Schmidt et al, 2022) of oxaliplatin or vehicle.